CALMponin – Novel markers for the diagnosis and prognosis of breast cancer

The invention is based on the finding that the proteins Calmodulin-like protein 5 (CALML5) and Calponin-h2 (CNN2) are upregulated in the nuclear matrix of human breast cancer tissue whereas both are absent in healthy human breast tissue and benign controls. Thus, the two proteins may serve as novel markers for breast cancer.

Comparing blood levels of patients with breast cancer, patients with benign breast diseases and age-matched healthy controls the use of CNN2 in human blood demonstrated to be a highly specific and sensitive biomarker for the early detection of human breast cancer in women of all ages. As CALML5 can also be found in human blood, a blood based assay identifying breast cancer patients by analysing the level of CALML5 is currently explored. Furthermore, this method may be used for the determination of a patient`s prognosis and of a therapy efficacy within the scope of personalized medicine.

Further Information: PDF

PROvendis GmbH
Phone: +49 (0)208/94105 10

Contact
Dipl.-Ing. Alfred Schillert

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Lighting up the future

New multidisciplinary research from the University of St Andrews could lead to more efficient televisions, computer screens and lighting. Researchers at the Organic Semiconductor Centre in the School of Physics and…

Researchers crack sugarcane’s complex genetic code

Sweet success: Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance in plants….

Evolution of the most powerful ocean current on Earth

The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….

Partners & Sponsors